Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Income from Continuing Operations of 13093000.0 in Q1 2026, down 12.73% quarter-over-quarter from 11614000.0 in Q4 2025, and down 183.23% on a YoY basis from 15732000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 13093000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 183.23% year-over-year to 13093000.0; the TTM figure through Mar 2026 stood at 42150000.0 (down 12.62% YoY), while the FY2025 annual figure was 13325000.0, up 77.45% from the prior year.
- Income from Continuing Operations was 13093000.0 for Q1 2026 at Corvus Pharmaceuticals, down from 11614000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 15732000.0 in Q1 2025 to a low of 39535000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 8224941.18 across 5 years, with a median of 7013000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 669.91% in 2024, then surged 364.98% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 5666000.0 in 2022, then advanced by 7.36% to 5249000.0 in 2023, then sank by 89.35% to 9939000.0 in 2024, then retreated by 16.85% to 11614000.0 in 2025, then fell by 12.73% to 13093000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13093000.0 (Q1 2026), 11614000.0 (Q4 2025), and 9834000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Corvus Pharmaceuticals | 1.01 Bn | 771.25 Mn | - | -13.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.61 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -7.61 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -39.54 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.94 Mn |
| Dec 31, 2023 | -5.25 Mn |
| Sep 30, 2023 | -5.14 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -12.47 Mn |
| Jun 30, 2022 | -7.01 Mn |
| Mar 31, 2022 | -7.41 Mn |
| Dec 31, 2021 | -6.81 Mn |
| Sep 30, 2021 | -9.05 Mn |
| Jun 30, 2021 | -11.29 Mn |